Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 10;99(28):e21041.
doi: 10.1097/MD.0000000000021041.

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis

Juan Li  1   2 , Guang-Hui Zhu  1   2 , Tong-Tong Liu  1 , Bo-Wen Xu  1   2 , Jie Li  1
Affiliations

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis

Juan Li et al. Medicine (Baltimore). .

Abstract

Background: Many research has indicated that some Chinese herb injections (CHIs) might be beneficial in combination with chemotherapy, however, with inconsistent results. Hence, the purpose of this network meta-analysis is to evaluate different CHIs plus cisplatin and gemcitabine (GP) with GP alone in terms of clinical efficacy and safety for treating patients with advanced NSCLC.

Methods: A comprehensive systematic search of clinical randomized controlled trials (RCTs) published in the PubMed, Embase, Web of Science (ISI), Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Database and China Biological Medicine Database (CBM) databases will be conducted to identify eligible studies up to the date of May 2020. The primary outcome measures objective response rate and adverse reactions (nausea and vomiting, leukopenia). The secondary outcome measures median survival time (MST), disease control rate, and quality of life. The methodological qualities, including the risk of bias, will be evaluated using the Cochrane risk of bias assessment tool, while confidence in the cumulative evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The network meta-analysis will be performed using WinBUGS 14 and Stata 15.1 software.

Results: Based on the current evidence, the potential rank of the efficacy and safety of CHIs plus GP chemotherapy for advanced NSCLC will be assessed, and a prioritization regimen will be summarized.

Conclusion: Evidence from this systematic review could be useful for patients, clinical practitioners, and guideline-makers to select an optimum proposal of CHIs plus GP for advanced NSCLC.

Ethics and dissemination: It is not necessary for ethical approval because it is based on published studies. The protocol will be disseminated in a peer-reviewed journal or presented at a topic-related conference.

Prospero registration number: CRD42020167142.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of studies search and selection. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed100009.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Li Y, Guo QS. Research progress of maintenance therapy in advanced non-small cell lung cancer. Chin J Cancer Prev Treat 2014;21:800–4.
    1. Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574-5p serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011;6:482–8. - PubMed
    1. Le CT. Adjuvant chemotherapy for resectable non-small cell lung cancer: where is it going? Ann Oncol 2010;21:196–8. - PubMed
    1. An ZJ, Guo CY, Chen MH, et al. Clinical observation of original chemotherapy for advanced non-small cell lung cancer between Changchun Swiss Bank combined with cisplatin regimen and docetaxel combined with cisplatin regimen. Chin J Med 2015;49:37–9.
    1. Huang TZ, Wang SZ, Yuan Y, et al. Analysis of related factors influencing survival time of patients with lung cancer. Chin Nurs Res 2016;30:4033–6.

MeSH terms